// App-Quantinova.ai

SAT-318 : Safety and Testosterone-Lowering Effects of the Investigational, Oral, GnRH Antagonist, TAK-385 in Healthy Male Volunteers: Results of a Phase 1 Inpatient/Outpatient Study

Researchers

Presenter

  • Hongliang Shi

Principal Investigators

  • Ajit Suri

  • Helene Faessel

  • Fred Saad

Medical Centers

  • University of Montreal, Montreal, QC, Canada

Locations

  • Canada

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Male Sexual Dysfunction

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Androgen Tear

  • TAK385

Outcome

  • N/A

Study Design

  • pharmacodynamics

  • randomized

  • double blind/blinded

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved